Abstract 92P
Background
Bone metastases (BM) from colorectal cancer (CRC) are often accompanied by extraosseous metastases and have a dismal prognosis. The present study aims to find out the risk factors for BM in metastatic CRC (mCRC) and the prognostic factors for CRC patients with BM.
Methods
The study was based on a training cohort of 214 mCRC patients (of which 101 patients with BM) from our center, and a validation cohort of 511 mCRC patients from another institution (of which 173 patients with BM). The risk and prognostic nomogram for BM were identified using univariate and multivariate analyses. The goodness of fit, discrimination and calibration performance of the nomograms were assessed by R2, concordance statistics (C-statistics) and the calibration curve. The results were internally validated using bootstrap resampling in the training cohort and externally validated in the validation cohort.
Results
The novel BM risk nomogram comprised of seven variables (degree of tumor differentiation, N_stage, serum ALP, LDH, CEA, liver metastasis and lung metastasis). It showed good performance with an R2 of 0.447 and a C-statistics of 0.846 (95% CI, 0.793 to 0.898) in the training cohort, and an R2 of 0.325 and a C-statistics of 0.792 (95% CI, 0.750 to 0.834) in the validation cohort. The optimal cutoff value to identify individuals at low or high risk was 56% probability with the sensitivity of 71.3% and specificity of 89.4%. The prognostic nomogram included five factors (tumor differentiation, No. of extra-BM organs, No. of BM lesions, ALP and LDH) with an R2 of 0.284 and a C-statistics of 0.723 (95% CI, 0.657 to 0.789) in the training set. This nomogram was externally validated in the validation cohort with an R2 of 0.182 and a C-statistics of 0.682 (95% CI, 0.638 to 0.726).
Conclusions
The developed and validated risk nomogram and prognostic nomogram show good performance on predicting the occurrence of BM in mCRC and prognosis in CRC patients suffered from BM. The risk nomogram can be used as a cost-effective preliminary screening tool prior to bone scan.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
144P - Clinical implication of DNA damage response gene in patients with stage II or III gastric cancer
Presenter: In Gyu Hwang
Session: e-Poster Display Session
145P - A nomogram for predicting the benefit of adjuvant chemotherapy after resection in patients with Borrmann type IV gastric cancer
Presenter: Qing-Zhu Qiu
Session: e-Poster Display Session
146P - Red cell distribution width and mean corpuscular volume ratio as a promising new marker for chemotherapy effects in remnant gastric cancer: An analysis of a multi-institutional database
Presenter: Kai-Xiang Xu
Session: e-Poster Display Session
147P - Can the clinical stage of the 8th edition of the Union for International Cancer Control TNM classification stratify prognosis of patients with Siewert type II/III cancer?
Presenter: Hayato Watanabe
Session: e-Poster Display Session
148P - MCV-the ideal answer to predict the prognosis of remnant gastric cancer: An analysis from a multi-institutional database
Presenter: Kai Weng
Session: e-Poster Display Session
149P - Molecular and clinical characteristics of patients with resectable gastric cancer
Presenter: Zhi Zheng
Session: e-Poster Display Session
150P - Real-world assessment of the treatment patterns associated with unresectable advanced and metastatic gastric cancer in China
Presenter: Xiao Sun
Session: e-Poster Display Session
151P - Treatment patterns, healthcare resource use, economic and survival outcomes associated with unresectable advanced metastatic gastric cancers in Taiwan
Presenter: Chee Jen Chang
Session: e-Poster Display Session
152P - ARID1A deficiency in EBV-positive gastric cancer is partially regulated by EBV-encoded miRNAs, but not by DNA promotor hypermethylation
Presenter: Koji Kase
Session: e-Poster Display Session
153P - Mutational landscape of gastric cancer (GC) in adolescents and young adults (AYA) in Asia from 2015-2019
Presenter: Evelyn Yi Ting Wong
Session: e-Poster Display Session